Actuate Therapeutics (NASDAQ: ACTU) published the results of its randomized Phase 2 trial of elraglusib in combination with gemcitabine‑nab‑paclitaxel (GnP) in the journal Nature Medicine. The study, registered as NCT03678883, enrolled 286 patients with previously untreated metastatic pancreatic ductal adenocarcinoma and randomized them 2:1 to receive elraglusib plus GnP or GnP alone.
The paper reports that the combination therapy doubled the 12‑month survival rate (44.1% versus 22.3%) and improved median overall survival to 10.1 months compared with 7.2 months for chemotherapy alone. Hazard ratio for death was 0.62 (p = 0.01), indicating a 38% reduction in the risk of death. These results provide independent validation of Actuate’s clinical strategy and strengthen the case for advancing elraglusib into a Phase 3 program.
Safety was manageable, with grade ≥ 3 neutropenia, anemia, and fatigue as the most common adverse events. Mild to moderate visual changes were observed but were transient and reversible, supporting the tolerability of the combination.
Daniel Schmitt, CEO of Actuate, said, “These Phase 2 results continue to reinforce elraglusib’s potential as a combination‑ready, first‑line therapy with the ability to enhance the activity of standard of care chemotherapeutic backbones.” He added, “The significant improvement in overall survival with an acceptable safety profile marks an important milestone for patients facing metastatic pancreatic cancer, historically one of the most difficult to treat diseases.”
Analysts revised earnings estimates upward following the publication, and price targets for the company now range from $6 to $25. The data are expected to influence investor sentiment and may support future financing efforts needed to fund the next development stage.
Elraglusib is a first‑in‑class GSK‑3β inhibitor that modulates tumor cell survival, reshapes the tumor microenvironment, and suppresses adaptive resistance pathways, potentially enhancing the activity of chemotherapy. Exploratory immunophenotyping in the trial showed significant increases in tumor‑infiltrating cytotoxic immune cells, suggesting an immunomodulatory mechanism of action.
The Phase 2 trial enrolled 155 patients treated with elraglusib plus GnP and 78 patients receiving GnP alone across 60 global sites. Actuate plans to advance elraglusib into a Phase 3 program based on these results, is exploring combinations with RAS and MEK/RAF inhibitors, and is preparing a Phase 1/2 program for an oral tablet form of elraglusib in the second half of 2026. Elraglusib has received orphan drug designation from the FDA for pancreatic cancer.
The publication of these Phase 2 survival data in Nature Medicine is a significant event for Actuate Therapeutics. The reported improvements in median overall survival and 12‑month survival rates, along with a reduced risk of death, provide strong evidence for elraglusib’s potential as a combination therapy for metastatic pancreatic ductal adenocarcinoma and are expected to be crucial for advancing the drug into Phase 3 trials and supporting regulatory submissions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.